NEW YORK (TheStreet) -- It's been a hot M&A market for biotech companies developing treatments for rare diseases. Nevertheless, Corbus Pharmaceuticals (CRBP) CEO Dr. Yuval Cohen says he is more focused on developing his cystic fibrosis drug Resunab than on dealmaking. 

"We can certainly choose to partner with a large pharmaceutical company or we can also do it on our own," says Cohen. "We have a small, but experienced and nimble team with the resources to take the drug all the way to market."

If you liked this article you might like

Did Corbus Investors Get Thrown Off by a Red Herring?

Home Depot, Federal Realty, more: 'Mad Money' Lightning Round

Market Stays Strong in the Fight: Cramer's 'Mad Money' Recap (Friday 4/7/17)

Taser, AMD, Amgen, Old Republic :'Mad Money' Lightning Round (3/30/17)

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)